Phase 3 Clinical Trials With Primary Completion Dates in August 2018

This is a list of Phase 3 trials with primary completion dates in August 2018 for companies with a market cap less than $1B. For complete clinical trial coverage, please see our Trial Tracker tool. It includes information on all clinical trials for publicly traded companies, screenable by stock symbol, market cap, disease, completion date, and phase.

The primary completion date is the date that the final subject was examined or received an intervention for the purposes of final collection of data for the primary outcome. It provides advance notice that a company will be announcing trial results in the near future.

SymbolCompanyPrimary Completion DatePhaseNCT IDTitle
AIMTAimmune Therapeutics, Inc.2018-08-01Phase 3NCT03126227Real-World AR101 Market-Supporting Experience Study in Peanut-Allergic Children
ALKSAlkermes plc2018-08-01Phase 3NCT02110264Injectable Pharmacotherapy for Opioid Use Disorders (IPOD)
AQXPAquinox Pharmaceuticals, Inc.2018-08-01Phase 3NCT02858453Efficacy and Safety of 2 Doses of AQX-1125 in Subjects With Interstitial Cystitis / Bladder Pain Syndrome
AVEOAVEO Pharmaceuticals, Inc.2018-08-01Phase 3NCT02627963A Study to Compare Tivozanib Hydrochloride to Sorafenib in Subjects With Refractory Advanced RCC
ENDPEndo International plc2018-08-01Phase 3NCT03446781Effectiveness and Safety of EN3835 in the Treatment of Cellulite in Women
ENDPEndo International plc2018-08-01Phase 3NCT03428750Effectiveness and Safety of EN3835 in the Treatment of EFP (Cellulite) in Women
ESPREsperion Therapeutics, Inc.2018-08-01Phase 3NCT02991118Evaluation of Long-Term Efficacy of Bempedoic Acid (ETC-1002) in Patients With Hyperlipidemia at High Cardiovascular Risk
FGENFibroGen, Inc2018-08-01Phase 3NCT02964936A Study of Intermittent Oral Dosing of ASP1517 in ESA-untreated Chronic Kidney Disease Patients With Anemia